Sorry, you need to enable JavaScript to visit this website.
Skip to main content

The asia-pacific cro

Take advantage of the world's fastest growing clinical trials region.

 

Location Settings

Asia-Pacific

AU -  Sydney
AU -  Melbourne
AU -  Brisbane
CN -  Hong Kong
CN -  Shanghai
IN -  Bangalore
MY -  Kuala Lumpur
PH -  Metro Manila
KR -  Seoul
CN -  Taipei City
TH -  Bangkok
NZ -  New Zealand

North America

US -  Boston

GLOBAL

English

CAREERS

SOLUTIONS

RESOURCES

ABOUT US

Location Settings

Asia-Pacific

AU -  Sydney
AU -  Melbourne
AU -  Brisbane
CN -  Hong Kong
CN -  Shanghai
IN -  Bangalore
MY -  Kuala Lumpur
PH -  Metro Manila
KR -  Seoul
CN -  Taipei City
TH -  Bangkok
NZ -  New Zealand

North America

US -  Boston

GLOBAL

English

Accelerating clinical trials with faster site selection and patient recruitment

Challenges

Sponsors in Europe and North America are facing increased challenges around participant recruitment and retention, lengthy timeframes and relatively high costs.

Asia-Pacific has become a key location for clinical trials, driven by its large patient population, scale of medical facilities, government support for clinical trials, strategic importance of Asian economies as end consumer markets, lower trial costs, and high-quality standards.

A multi-award winning regional contract research organization (CRO)

2021-best-practices-award
2021 CRO Leadership Award
2020 Asia Pacific Biotech CRO Company of the year (Frost & Sullivan)

Where We operate

  • Asia-Pacific
  • North America
Australia

Australia

  • High quality research, facilities and equipment
  • Fast set-up and approval times
  • Sponsor can claim R&D cash refund
Greater China

Greater China

  • Very large, homogenous population
  • Strong focus of NMPA (previously CFDA) on shortening regulatory timelines
  • Largest clinical trial hub in Asia, with over 17,000 active investigators 
     
India

India

  • Large treatment-naïve population
  • High disease population load
  • The clinical activity grew by over 40% in 2018 on the back of regulatory pathway improvements
  • About 1,800 investigators have participated on a minimum of 5 studies
Malaysia

Malaysia

  • Multiethnic Asian population
  • Streamlined regulatory system and Strong govt. support 
  • Quick start-up timelines
  • Low patient costs and IRB fees
Philippines

Philippines

  • Large treatment-naïve population
  • Low costs
  • Overall good level of English
Singapore

Singapore

  • Multiethnic Asian population 
  • Regional clinical research hub
  • Efficient regulatory process and good infrastructure
South Korea

South Korea

  • Homogenous and concentrated population 
  • High quality medical services and excellent infrastructure
  • The most active Asian country in clinical research after China, with over 400 sites opened by biopharmas companies in 2018
Thailand

Thailand

  • Large homogenous population 
  • High prevalence of communicable diseases
  • Efficient regulatory system
  • Low operational cost
United States of America

United States of America

 

Novotech has two customer facing offices
on both the East Coast and West Coast.

New Zealand

New Zealand

  • High-quality research, facilities and equipment
  • Fast set-up and approval times
  • Sponsor can claim R&D cash refund

Our Company

"Novotech is a great place to build a career. We are very focused on providing motivating work, having an inclusive culture, a flexible workplace, and very high levels of transparency with our people.  I am absolutely committed to Novotech being a leader in gender equality which is a key part of our workplace philosophy."

- Dr. John Moller

Chief Executive Officer, Novotech CRO

Our Latest Reports

close HOLD THE DATE! Oct 21, 2021, Endpoint Webinar on driving efficiencies through virtual trial solutions in Asia Pacific.